The Mader Group Ltd (ASX: MAD) share price is in focus today after the company reported record FY26 revenue of $1.0 billion and net profit after tax (NPAT) of $65.4 million, both up 15% from last year.

What did Mader Group report?

• Revenue of $1,001.1 million, up 15% on the prior corresponding period (PCP)
• NPAT of $65.4 million, a 15% increase versus last year
• EBITDA of $120.7 million, rising 10% year on year
• Net cash position of $35.7 million, compared to net debt of $8.3 million in FY25
• No final dividend declared for FY26

What else do investors need to know?

Mader Group’s Australian business continued to grow, with services expanding across infrastructure and road transport. High-growth verticals and a strong market presence helped drive a 16% revenue increase in Australia.

In North America, revenue rose 12% (or ~17% in constant currency), supported by record headcount and expanding operations, especially in Canada. The Rest of World segment remains strategically important, with new business pursued in regions like New Zealand and Asia.

The company reported a Total Recordable Injury Frequency Rate of 3.65 per million hours and invested further in safety initiatives and community engagement, including support for events like the Mader Port to Pub and partnerships with Ronald McDonald House Charities and local Indigenous businesses.

What did Mader Group management say?

Executive Director & Chief Executive Officer Justin Nuich said:

I’m proud to announce that we have surpassed $1 billion in annual revenue, marking the successful delivery of the five-year strategic plan established by the Board in 2021… Achieving this milestone is a reflection of our people, our customers and a business model that continues to perform at scale… Looking ahead, with a strong culture, diversified service offering, and a scalable global platform, we are well-positioned to build on this momentum, capture the opportunities in front of us and continue to deliver long-term value for our shareholders.

What’s next for Mader Group?

The outlook for FY27 is upbeat, with Mader targeting at least $1.13 billion in revenue and NPAT of $72.5 million—growth of 13% and 11%, respectively. The company is investing in new service lines, growth initiatives, and an expanded long-term incentive program to underpin its ambition for approximately 15% compound annual growth over the next five years.

While no FY26 dividend was declared, the board continues to review capital allocation, and management remains focused on expanding Mader’s capabilities, strengthening its position in key markets, and supporting sustainable long-term growth.

Mader Group share price snapshot

Over the past 12 months, Mader Group shares have declined 13%, trailing the All Ordinaries Index (ASX: XAO), which has risen 1% over the same period.

View Original Announcement

The post Mader Group FY26 earnings: Profit jumps 15% on record revenue appeared first on The Motley Fool Australia.

More reading

• Tyro Payments FY26: Earnings rise, growth outlook improves
• ARB Corporation shares: FY26 profit drops but growth investments strengthen outlook
• Southern Cross Gold reports drilling results
• Viva Energy Group posts record 1H26 earnings, boosts dividend
• Scentre Group shares on watch as 2026 half year earnings climb and guidance gets a boost

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Mader Group. The Motley Fool Australia has positions in and has recommended Mader Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Scentre Group (ASX: SCG) share price is in focus today after the company reported funds from operations (FFO) of $612 million for the first half of 2026, up 4.4%, and upgraded its full year guidance for both earnings and distributions.

What did Scentre Group report?

• FFO for the half year: $612 million, up 4.4% (11.73 cents per security)
• Distribution for the half: $481 million, up 4.9% (9.215 cents per security)
• Statutory profit: $975 million, boosted by an unrealised property valuation increase of $478 million
• Annual customer visitations reached 552 million, a record for the business
• Occupancy remained high at 99.8%, the best in over a decade
• Upgraded 2026 full year guidance to at least 23.79 cents FFO and a distribution of 18.473 cents per security

What else do investors need to know?

Scentre Group delivered solid customer engagement and strong operational metrics. Customer advocacy improved, with its Net Promoter Score rising 12 points to 65, and Westfield membership grew to 5.2 million, up 11% on the previous year.

The group completed 1,401 leasing deals, with average specialty rent escalations of 5.5%. Business partners’ sales for the year reached a record $30.3 billion, growing 4.2% year on year. Scentre remains highly engaged in ongoing redevelopments at key destinations, including Westfield Bondi, Penrith, and Tuggerah.

On the capital management front, Scentre successfully introduced Australian Retirement Trust as a joint venture partner at Westfield Mt Gravatt and reduced its average debt margin from 2.6% to 1.6%. There is ample liquidity, with $3.5 billion available and all pandemic-era debt refinanced.

What did Scentre Group management say?

Scentre Group CEO Elliott Rusanow said:

Our focus is to continue generating long term earnings growth from our Westfield business in Australia and New Zealand and create significant additional value from our substantial land holdings.

What’s next for Scentre Group?

Management has upgraded full year 2026 FFO and distribution guidance, pointing to growth of at least 4.25%. Scentre is continuing to invest in its retail destinations and progress major redevelopments, especially at Westfield Bondi and other key sites.

At the same time, the group is looking to unlock value from its strategic land holdings by progressing plans to deliver up to 25,600 dwellings, working collaboratively with governments on housing supply. Scentre also aims to strengthen partnerships and drive further economic activity in and around its Westfield centres.

Scentre Group share price snapshot

The Scentre Group share price has underperformed the S&P/ASX 200 index (ASX: XJO) on a 12-month basis with a decline of around 8%.

View Original Announcement

The post Scentre Group shares on watch as 2026 half year earnings climb and guidance gets a boost appeared first on The Motley Fool Australia.

More reading

• Scentre Group sells 50% stake in Westfield Mt Gravatt to ART

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

Shares in Medical Developments International Ltd (ASX: MVP) are down slightly more than 20% over the past 12 months, but according to the analysts at Bell Potter there could be some serious upside from here.

Bell Potter has a buy recommendation on the shares and a bullish share price target which I’ll get to shortly. First let’s look at the company’s recently-released full year results.

Modest uplift in earnings

MVP last week announced a net profit of $600,000 for FY26, up from $100,000 for the previous year.

The company’s revenue was up 9% to $42.6 million.

The company’s main business involves the manufacture and sale of Penthrox, better know as the “green whistle” pain relief device.

MVP said in FY26 there was 28% volume growth of Penthrox in the Australian hospital segment and 18% growth in the European market.

Chief Executive Officer Brent McGregor said of the results:

We have delivered a solid financial performance in FY26 with strong cashflow generation. In our Pain Management segment we saw pleasing underlying growth, with stronger volumes in all regions. While demand in our Respiratory business was soft, pricing initiatives and lower costs helped deliver a modest improvement in segment earnings. Accelerating Penthrox volume growth was our priority in FY26. We are delighted by the progress we have made in the period on several important initiatives. This included obtaining regulatory approval for the paediatric indication of Penthrox in the UK and Europe. Penthrox can now be used by children 6 years of age and older in these markets – an important milestone for the Company. We expect to see benefits from access to the broader addressable market in future periods.

For FY27 MVP said it expected higher demand for Penthrox in Europe, “supported by the paediatric indication in Europe and the recently published health economic data”.

The company said the impact to earnings of Middle East supply chain disruptions and US tariffs remained uncertain and continued to be monitored.

Shares looking cheap broker says

Bell Potter said in a note to its clients that the result was broadly in line with their expectations, but they added that the company was poised for growth.

They said:

The completion of the transition in the European distribution arrangements for Penthrox lays a foundation for MVP to focus on improving demand and utilising the recent health economic analysis, published in “Emergency Medicine Australasia” to accelerate hospital adoption across geographical markets. MVP will be seeking to selectively open new markets, leveraging existing approvals and work towards improving the economic value of Penthrox.

Bell Potter has a price target of $1 on MVP shares compared to 50 cents currenty.

MVP is valued at $56.3 million.

The post This ASX small cap healthcare stock is tipped to double in value appeared first on The Motley Fool Australia.

More reading

• Tyro Payments FY26: Earnings rise, growth outlook improves
• ARB Corporation shares: FY26 profit drops but growth investments strengthen outlook
• Southern Cross Gold reports drilling results
• Viva Energy Group posts record 1H26 earnings, boosts dividend
• Mader Group FY26 earnings: Profit jumps 15% on record revenue

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Medical Developments International. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.